Janssen Biotech, Inc. announced a supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) has been submitted to the U.S. Food ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE